Society of Hematologic Oncology (SOHO) shared a post on X:
On the July FDA ODAC vote, Al-Ola A Abdallah says that ODAC ‘acknowledged the fact that the treatment has been fairly effective…’ watch the full interview on SOHO Insider.”
Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared this post, adding:
“An interview with Society of Hematologic Oncology regarding new approval of Belantamab at USMIRC News.”
More posts featuring Al-Ola A Abdallah.